Aura Biosciences 定价 3950 万股普通股和认股权证，筹集近 3 亿美元
Read, Watch or Listen
Boston — Aura Biosciences announced on May 4 that it priced an underwritten public offering of common stock and pre-funded warrants, offering 39,591,000 shares and up to 3,800,000 pre-funded warrants at $6.00 and $5.99999 respectively; the company granted underwriters a 30-day option for additional shares. Boston and Philadelphia reports this week show related financing activity in the biotech sector: Aura reported the offering closed on May 5 with full exercise of the underwriters’ option, generating approximately $299.4 million in gross proceeds, while Cabaletta priced an at-the-market offering on May 4 expected to raise about $150 million with institutional participation, including Eli Lilly.
Prepared by Christopher Adams and reviewed by editorial team.
Timeline of Events
- 2026年5月4日 — Aura通过GlobeNewswire宣布了承销的公开发行计划。
- 2026年5月4日 — Cabaletta Bio定价了一项按市值发行的募集约1.5亿美元的计划。
- 2026年5月4日 — Aura定价了39,591,000股股票和高达3,800,000份的预付费认股权证，价格分别为6.00美元/5.99999美元。
- 2026年5月5日 — Aura完成了发行，承销商已完全行使期权；总募集资金约2.994亿美元。
- 2026年5月5-6日 — 新闻媒体发布了定价和发行完成通知，列出了承销商和参与的投资者。
Why This Matters to You
Aura 和 Cabaletta 的这些公开募股是生物技术领域的重要举措。它们显示了投资者的信心，这可能影响股市。如果您投资于生物技术领域或正在考虑，请密切关注这些公司。
The Bottom Line
Aura 和 Cabaletta 的成功发行筹集了大量资金，预示着生物技术市场将蓬勃发展。这是回顾您的投资策略的好时机。如果您认识对生物技术股票感兴趣的人，值得转发。
- Articles Published:
- 2
- Right Leaning:
- 0
- Left Leaning:
- 0
- Neutral:
- 2
- Distribution:
- Left 0%, Center 100%, Right 0%
Aura Biosciences 和 Cabaletta Bio 从机构和战略投资者那里获得了新资金，而承销商和参与的投资公司则获得了承销费和配售份额。
Aura 的现有普通股股东的股权被稀释，因为公司发行了额外的普通股和预付费认股权证，导致现有持股比例下降。
Coverage of Story:
From Left
No left-leaning sources found for this story.
From Right
No right-leaning sources found for this story.
Comments